Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Don't Floss, You Lose - (ATRX) To the RESCUE. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (173)	4/15/2002 9:06:32 AM
From: Arthur Radley	Read Replies (1) \| Respond to of 182

Tuck, ATRX has been good to me..since I bought in below $10.00. I must admit that I originally bought in because of their dental products, but soon found out that dentists are hard to change from proven methods and especially methods that bring in the big bucks, as opposed to a drug treatments. What their product would do, would eliminate the surgical procedure that they could charge more. Also, it became apparent that the marketing agreement with Block was a bad decision. They now have a new marketing team...so things might get better in the future....MIGHT! As for the Eligard product....their delivery system might make it a winner, plus the fact they have the first FDA approval already and two others pending. Also, their acne product looks very promising. In total they have a fairly deep pipeline, but at these levels I think the shares are fully valued.